SecBot SecBot
PRESS-RELEASE ·Filed Aug 11, 2026

TNGX

Tango Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The 92% ORR data in pancreatic cancer is the primary catalyst, watch for ESMO presentation in October and Phase 3 design announcement in 2H 2026. The $1.0B cash runway removes near-term dilution risk. Monitor for any regulatory feedback on the registrational path and lung cancer monotherapy data later this year.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

ERAS-0015

◆ Mixed Named in this press release
Impact
Phase
Phase 1
Time to market
~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
Next catalyst
None dated

What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$26.34
T+0 close · Aug 11, 2026 · via day close
Latest settled
−12.00%
T+60 · $23.18
Vs SPY
−11.51%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $26.34entry
  2. T+1 · 3mo ago −2.89%α −3.14% · $25.58
  3. T+5 · 3mo ago −3.42%α −3.01% · $25.44
  4. T+20 · 2mo ago −8.88%α −7.82% · $24.00
  5. T+60 · 13d ago −12.00%α −11.51% · $23.18
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tango Therapeutics reported Q2 2026 net loss of $0.37 per share, slightly wider than the $0.35 loss in Q2 2025, with zero collaboration revenue as the Gilead deal concluded. The key catalyst is the 92% objective response rate for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer, driving plans for a Phase 3 trial and a $1.0B cash runway through commercialization. The stock's move hinges on the ESMO data presentation and Phase 3 design finalization in 2H 2026, not the financial results themselves.

Key Financial Metrics

EPS
−$0.37
est −$0.31 · -19.4%
Revenue
$0.00
est $0.00
Rating
in line

Key Facts

  • Net loss of $55.3M ($0.37/share) for Q2 2026 vs $38.9M ($0.35/share) in Q2 2025
  • Cash position of $1.0B as of June 30, 2026, expected to fund current operating plan
  • Vopimetostat + daraxonrasib achieved 92% objective response rate and 90% six-month PFS in MTAP-deleted, RAS-mutant pancreatic cancer
  • Company initiating dialogue with regulators for registrational path; Phase 3 trial design to be finalized in 2H 2026
  • Phase 1/2 data to be presented at ESMO Congress October 23-27, 2026
  • Appointed Fatma Ocak as Chief Commercialization Officer and Robert Azelby as Chairman of the Board
  • Research and development expenses increased to $37.2M from $32.8M year-over-year
  • General and administrative expenses doubled to $22.6M from $11.3M year-over-year

Financial Impact

Net loss widened by $16.4M year-over-year to $55.3M; cash burn rate approximately $50M per quarter; $1.0B cash runway provides ~5 years of funding at current burn

net losscash positionR&D expensesG&A expenses

Risk Factors

  • Clinical trial failure in Phase 3 or regulatory setback
  • Dependence on Revolution Medicines' RAS(ON) inhibitors for combination therapy
  • Widening losses and increasing G&A expenses without near-term revenue
  • Competition from other PRMT5 inhibitors and RAS-targeting therapies

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3342532

Track record

27 reports on TNGX

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
  4. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
  6. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  7. Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
  9. Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
  10. Aug 11, 202613w ago 8-K Bullish 7/10 No price data
Showing 10 of 27

US Market Status

Market Closed · Opens in 9h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026